elagolix

Neurocrine Biosciences, elagolix, hyperplasia, phase 3 trial data, FDA, uterine cancer, congenital adrenal hyperplasia

Neurocrine advances potential blockbuster drug for endometrial hyperplasia after phase 3 success

Anika Sharma

Neurocrine Biosciences is banking on its hyperplasia drug, crinecerfont, which analysts predict could be a blockbuster. The company has been ...